MedTrace Logo

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

NCT07354477 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-07-06

No results posted yet for this study

Summary

Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG

Conditions

  • Non-proliferative Diabetic Retinopathy (NPDR)
  • Open-angle Glaucoma (OAG)
  • Normal Tension Glaucoma (NTG)

Interventions

DRUG

QLS-111 Ophthalmic Solution (0.015%)

QLS-111 (0.015%) administered BID for 7 days OU.

DRUG

QLS-111 Ophthalmic Solution (0.075%)

QLS-111 (0.075%) administered BID for 7 days OU. Follows the 7 days where QLS-111 (0.015%) is administered.

Sponsors & Collaborators

  • Qlaris Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Barbara M Wirostko, MD · Qlaris Bio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-20
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07354477 on ClinicalTrials.gov